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DII, Dietary inflammatory index 
CHD; coronary heart disease  
IL; interleukin 
AMI; acute myocardial infarction 
CRP; C-reactive protein 
MedDiet; Mediterranean diet  
MetS; Metabolic syndrome 
BMI; body mass index  
CONSORT, Consolidated Standards of Reporting Trials 
MUFA; monounsaturated fatty acids  
PUFA; polyunsaturated fatty acids  
MEDAS; Mediterranean Diet Adherence Screener 
MVPA, moderate-to-vigorous physical activity  
DXA; Dual-energy X-ray Absorptiometry 
VAT; Visceral adipose tissue 
SAT; subcutaneous adipose tissue 
SBP; Systolic blood pressure 
DBP; diastolic blood pressure 
LDL; low-density lipoprotein 
HDL: high-density lipoprotein 
Hs; high sensitivity  
ELISA; enzyme‐linked immunosorbent assay 
T2DM; type 2 diabetes mellitus  
SD; standard deviation  
IQR; interquartile range  
OR; odds ratio  
CI; confidence interval 
ANOVA; analysis of variance  


























The Dietary Inflammatory Index (DII
®
) was designed to measure the inflammatory potential 
of one’s diet.  Evidence from observational studies supports that a higher (i.e., more pro-
inflammatory) DII score is associated with inflammation and cardiometabolic diseases. We 
hypothesized that reduction in DII score would improve inflammatory cytokines. To test this 
hypothesis, we assessed data from a dietary intervention trial in patients with diagnosed 
coronary heart disease (CHD) to determine whether reduction in DII scores through healthy 
diets is linked to improvement in inflammatory and related cardiometabolic risk markers. 
Participants (n=65, 83% male) were randomized to a Mediterranean diet or low-fat diet 
interventions for 6-months. Anthropometry, body composition and blood markers were 
measured and DII scores were calculated from 7-day food diaries. After 6-months, in 
participants who completed the intervention (n=56), reduction in DII score correlated 
significantly with high sensitivity interleukin-6 (hs-IL-6) (r=0.34, 95%CI 0.05, 0.56) and 
triglycerides (r=-0.30, 95%CI -0.51, -0.06) but not with C-reactive protein, adiponectin, 
glucose, body composition or anthropometry. The adjusted mean difference in hs-IL-6 and 
triglycerides between the highest and lowest tertiles of DII improvement was -0.47pg/mL 
(95%CI 0.41, 1.10 ) and +0.30mmol/L (95%CI 1.06, 1.59), respectively. The present study 
found that improvement in DII score through healthy diet intervention was linked with 
reduced levels of hs-IL-6, but also increased triglycerides, in adult Australian patients with 
CHD. Future research is warranted to investigate the impact of change in DII on 
cardiometabolic risk markers in larger cohorts, other disease populations or healthy subjects 
and with longer-term follow up.   

















Chronic, low-grade, systemic inflammation is recognized as an underlying 
pathophysiological cause of coronary heart disease (CHD)[1]. Inflammatory markers are 
involved in both atherogenesis as well as vulnerability of plaque to rupture and consequent 
acute myocardial infarction (AMI)[2, 3]. Inflammatory markers have therefore emerged as 
targets for treatment of CHD in addition to classic risk factors such as cholesterol and blood 
pressure[4, 5].  
 
Nutrition, especially adherence to dietary patterns, can have an impact on inflammation[6-8]. 
The Dietary Inflammatory Index (DII
®
) was designed specifically to measure the 
inflammatory potential of one’s diet[9]. Derived from review of the diet-inflammatory 
marker literature, this index is based on identifying 45 known nutrient/food intake parameters 
which have either a pro- or anti-inflammatory effect on a range of inflammatory biomarkers. 
The DII was validated based on its ability to predict elevated C-reactive protein (CRP) levels 
(>3 mg/L)[10]. Other studies have investigated the association between higher DII scores 
(indicating more pro-inflammatory diets) and elevated CRP with mixed results[11, 12]. The 
DII has also been shown to be associated with the inflammatory markers interleukin (IL)-6 
and tumor necrosis factor-α [13, 14]. Higher DII scores have been positively associated with 
blood pressure, triglycerides and incident metabolic syndrome (MetS)[15], obesity[16, 17] 
and CHD[18-21]. 
 
The DII also has been investigated against dietary pattern scores and other cardiovascular 
disease risk markers and outcomes[22]. A lower DII has been linked to healthy low-fat diet 














published studies have investigated the effect of diet intervention on DII, demonstrating a 
short-term improvement with vegetarian diets[25] and modest long-term improvement with a 
low-fat diet[26]. Recent analyses from the current study, demonstrated that 6-month MedDiet 
intervention in Australian CHD patients significantly improved DII scores (more anti-
inflammatory values), whereas a low-fat diet did not [27].    
 
Despite strong evidence from observational studies, there is limited evidence from 
intervention trials to support that reduction in DII scores through dietary change leads to 
improvements in inflammation or related health risk factors[19, 28-31]. In the context of 
CHD, one could assume that a reduction in DII could improve disease risk associated with 
inflammation. However, the possible anti-inflammatory effect of an improvement in DII may 
be limited in patients diagnosed with CHD[8], as current CHD medication regimes have 
pleiotropic anti-inflammatory effects[32, 33]. Our previous analysis found that the 
theoretically anti-inflammatory MedDiet intervention did not lead to a significant reduction 
in CRP or IL-6 compared to a low-fat diet[27]. Our primary aim in this paper was to 
investigate specifically whether reduction in DII score following 6-month dietary intervention 
with these healthy diets (in the pooled study cohort) was associated with improvement in 
inflammatory and related cardiometabolic risk markers in adult patients with CHD. Our 
primary hypothesis was that participants with CHD who had the greatest reduction in DII 
score would experience the greatest reduction in inflammation. Our secondary aims were to 
elucidate which nutrient and food group changes were linked to improved DII following diet 
intervention, and to determine which sociodemographic and clinical characteristics may be 
associated with DII score in a CHD cohort.  
 















2.1. Study Design  
 
The AUStralian MEDiterranean Diet Heart Trial (AUSMED Heart Trial) is a parallel design, 
randomized controlled trial for the secondary prevention of CHD (Australia and New Zealand 
Clinical Trials Register: ACTRN12616000156482, http://www.anzctr.org.au/). In a multi-
ethnic Australian population consisting of individuals who have experienced a cardiac event, 
the trial delivers a 6-month intervention with a MedDiet versus low-fat diet. The primary 
outcome is an aggregate of cardiovascular events at 12-month follow-up and secondary 
outcomes include intermediate markers of cardiometabolic risk and diet adherence at 6 
months. In a pilot cohort of AUSMED participants, the present study explores whether 
improvement in DII through healthy diet intervention is associated with improved risk factors 
for CHD after 6-months. In the following analyses the diet study groups have been pooled so 
that the effect of change in DII score, rather than the individual dietary interventions, on risk 
markers could be elucidated.  
 
Our protocol was approved by the Human Research Ethics Committees of La Trobe 
University, the Northern Hospital and St Vincent’s Hospital Melbourne. The nature and risks 
of the study procedure were explained to each participant, and all participants provided 
written informed consent prior to enrollment. The study is being conducted in accordance 
with the CONSORT guidelines[34] and the guidelines of the Declaration of Helsinki[35].   
 















Details regarding eligibility criteria and recruitment have been detailed elsewhere[27]. 
Briefly, patients were recruited from two teaching hospitals in Melbourne, Australia from 
2014 to 2016. Eligible patients were adults with CHD who had experienced at least one of the 
following: AMI, coronary artery bypass grafting, percutaneous coronary intervention (with or 
without stenting) or angina pectoris with documented coronary artery disease on imaging. 
Exclusion criteria included: symptomatic chronic heart failure (New York Heart Association 
Functional Classification II, III & IV[36]), chronic inflammatory disease, chronic kidney 
disease stage 3 or above[37], decompensated liver disease, malignant tumor, pregnancy or 
breastfeeding, inability to read and write in English, or current participation in a lifestyle 
program (including cardiac rehabilitation), drug or supplement trial.  
 
Eligible and interested patients attended a pre-baseline appointment where consent was 
obtained and randomization was conducted. Randomization to diet study groups was based 
on a computer generated stratified approach including gender, age and history of AMI. 
 
2.3. Diet interventions 
 
During the trial all participants continued to receive their standard medical care provided in 
primary care settings or at their respective treating hospital. Face-to-face appointments were 
conducted at baseline, 3-months (mid-intervention) and 6-months (end-intervention) for 
dietetic counselling and to conduct study measures. Five phone reviews with the dietitian also 
occurred across the 6-months at weeks 3, 6, and 9 and months 4 and 5. Consultation 
frequency and data collection time points were consistent across the two diet study groups. 
Meal plans were provided as a guide only as participants were provided with individualized 














prescribed ad libitum, without energy restriction, and exercise was not a target of either 
intervention. This paper was not designed to distinguish the effect of intervention on DII 
between the diet study groups as this has been reported elsewhere[27]. A brief description of 
the two diet interventions is given here to provide an overview of the healthy diet 
recommendations given to participants. 
 
2.3.1. Mediterranean diet 
 
The diet was designed based on the principles of a traditional Cretan MedDiet[38] with 
reference to MedDiet trials[39-42] and dietary guidelines of Greece[43]. A model diet was 
created as a 2-week meal plan incorporating key dietary components of a MedDiet and a mix 
of traditional and modified recipes[44]. Macronutrient intake targets were 42% total fat, of 
which at least 50% was from monounsaturated fatty acids (MUFA) and 25% from 
polyunsaturated fatty acids (PUFA), 35% carbohydrate, 15% protein, <10% saturated fatty 
acids, and ≤5% alcohol as contributions to total energy consumption. In addition to the 2-
week meal plan participants were provided with a recipe book (Itsiopoulos, 2013, ISBN 
9781742610825) and shopping list, food group pyramid and food-label reading resources 
which were designed for this intervention.  
 
The MedDiet specifically included promotion of extra virgin olive oil, nuts, leafy greens, 
tomatoes, onion, garlic, legumes, oily fish and fermented dairy foods, and significantly 
reduced intake of red meat, which were not key components of the low-fat diet[45]. At 
baseline and mid-intervention appointments, a food hamper was provided to participants 














oil (to achieve 60-80mL/day) and samples of canned legumes, tinned tuna and salmon, and 
Greek yoghurt. 
 
2.3.2. Low-fat diet 
 
Participants in the low-fat diet group were instructed to follow the standard diet 
recommendations provided to cardiac patients. Australian recommendations from the 
National Heart Foundation as well as Dietary Guidelines and Nutrient Reference Values were 
consulted for design of the diet[46-48]. Macronutrient intake targets were <30% total fat, 
<7% saturated fat, 45-65% carbohydrate, 15-25% protein and ≤5% alcohol as contributions to 
total energy consumption. Food group recommendations included  daily intake of grains and 
cereals (mostly whole grains, 5-7 serves/day), vegetables (5-6 serves/day), fruit (2 
serves/day), protein foods (2-3 serves/day) and low-fat dairy foods (2 serves/day)[47]. A 1-
week meal plan was created to model this diet for participants. Additional resources were 
provided for recommended daily food group serves, label reading and low-fat cooking. To 
aid participant dietary compliance and continuation in the trial, individuals were provided 
with a supermarket voucher at each face-to-face appointment. 
 
2.4. Study Measurements  
 
This study reports on baseline and end-intervention data measurements only. Data on medical 
conditions was collected from medical records and in consultation with hospital staff during 
the screening process, and via a questionnaire at the pre-baseline appointment. Participants 
completed a self-report survey prior to their baseline appointment which recorded 














characteristics. A modified version of the survey was completed at the end-intervention 
appointment, which re-assessed lifestyle and clinical characteristics.  
 
2.4.1. Dietary assessment  
 
Our methods for assessing dietary intake and calculation of the DII score also have been 
detailed previously[27]. Briefly, the week prior to the baseline and end-intervention 
appointments, participants completed a 7-day food diary in household measures. The diary 
included quantity, type, brand and cooking methods for consumed foods with unclear details 
clarified by the dietitian. All food diaries were entered into FoodWorks8
®
 (Xyris software 
Australia Pty Ltd) for nutrient and food group intake analyses. Food group serve sizes were 
based on FoodWorks8 data[49]. The 14-point Mediterranean Diet Adherence Screener 
(MEDAS), generated and validated for the PREDIMED study[50], was measured at baseline 
and end-intervention for each participant. 
 
2.4.2. Dietary Inflammatory Index (DII®) 
 
The development[9] and validation[10] of the DII has previously been reported. Peer-
reviewed literature published between 1950 to 2010 was evaluated and 1943 articles 
identified 45 individual nutrient, food or flavonoid intake that were associated with six 
established inflammatory biomarkers; IL-1β, IL-6, tumor necrosis factor-α, CRP, IL-4 and 
IL-10. Points were assigned to each of these parameters according to whether they increased, 
decreased or had no effect on each of the six inflammatory biomarkers.  The score for each of 
the food parameters was weighted based on the study designs and total number of research 














on the ratio of the total weighted number of articles to the weighted pro- and anti-
inflammatory articles for that parameter, followed by subtracting the anti-inflammatory 
fraction from the pro-inflammatory fraction. The inflammatory effect score of each parameter 
was then mediated against its number of weighted articles. 
 
Our assessment of the DII included all of its 45 parameters. Dietary intake data were adjusted 
against a reference global daily mean and standard deviation (SD) intake for each parameter 
to obtain a Z-score. The global intake data was based on consumption data from 11 countries. 
To reduce the effect of right-skewing of the dietary data, the z-score was then expressed as a 
proportion (i.e., with value from 0 to 1).  Centering these scores on zero (0) was achieved by 
doubling the proportion and subtracting one (1). The resulting centered proportion score for 
each intake parameter was multiplied by its respective parameter-specific inflammatory effect 
score and then each of these 45 scores were summed to obtain an overall DII score for each 
participant. Finally, the DII scores were re-calculated with the inclusion of nutrient 
supplement intake (DIIdiet+supplements).  
 
In this study, the DII was measured at baseline and end-intervention. The intake values for 
most of the DII parameters (energy, protein, carbohydrate, total fat, MUFA, PUFA, omega-3, 
omega-6, saturated fatty acids, trans fat, cholesterol, fiber, alcohol, caffeine, folate, beta 
carotene, vitamin A, vitamin B6, vitamin B12, vitamin C, vitamin E, iron, magnesium, 
niacin, riboflavin, selenium, thiamin and zinc) were obtained from FoodWorks8 nutrient 
analyses of the food diaries. Isolated food components in the DII (green/black tea, garlic, 
ginger, onion, pepper, rosemary, saffron, turmeric and thyme/oregano) were extracted from 
the food diaries and the total daily intake in grams calculated. Vitamin D was calculated 














based on the recognized content in cloves in Phenol Explorer[52]. For calculation of 
flavonoids (flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins and isoflavones) the 
USDA Databases for the Flavonoid Content of Selected Foods (Release 3.2, November 2015) 
and Isoflavone Content of Selected Foods (Release 2.0, September 2008) were used..  
 
2.4.3. Cardiometabolic risk markers  
 
Activity levels, anthropometry, body composition and blood pressure were measured and a 
blood sample collected at baseline and end-intervention appointments. Participants wore a 
triaxial Actigraph accelerometer (WGT3X-BT; Actigraph Corp, Florida, United States) for 
one week prior to their appointments. Established criteria[53] were used to determine time 
spent as moderate-to-vigorous physical activity (MVPA) minutes per week and as sedentary 
hours per week. Anthropometry measures were performed according to the International 
Society for the Advancement of Kinanthropometry standards by trained research personnel 
[54]. Body weight was measured to the nearest 0.1kg using calibrated digital scales after an 
8-h fast, without shoes and after removal of heavy jewelry, outer layers of clothing and 
pocket contents. Height was measured to the nearest 0.1cm, while barefoot, using a wall-
mounted stadiometer. Two measures of waist circumference directly over the skin at the level 
of the narrowest point between the lower costal (10th rib) and top of the iliac crest were taken 
to the nearest 0.1cm, and the average calculated. If the two measures differed by 2% or more 
a third measure was taken and the average of all three measures calculated.  
 
Whole body composition was measured using a fan beam densitometer Dual-energy X-ray 
Absorptiometry (DXA) machine (Hologic, Discovery W), with analysis performed using 














a trained licensed technician who had undergone DXA and radiation training. Procedures and 
positioning of participants on the scanning bed were standardized according to 
recommendations of the Australian and New Zealand Bone and Mineral Society and 
manufacturer guidelines. Participants were required to be fasted for at least 8 hours, void their 
bladder, wear light clothing free from metal and remove shoes, jewelry, watches, glasses and 
hearing aids. Participants were instructed to lie supine on the scanning bed with slight 
internal rotation of legs from the hip, with arms straightened by the sides and palms flat on 
the bed or placed against thighs. All scans were conducted in the normal length and standard 
thickness mode with regions of interest and analyses automatically generated by the software. 
Three measurements were obtained from each scan: total body fat percentage, subcutaneous 
adipose tissue (SAT) area and visceral adipose tissue (VAT) area. Hologic scientists 
developed their method for measuring VAT from DXA[55], which is highly correlated 
(r=0.93) and linearly related to VAT measurements by computed tomography[56].  
 
Anthropometry measures were performed according to the International Society for the 
Advancement of Kinanthropometry standards by trained research personnel 
[54].Measurements were taken at least at 1 min intervals after the participant had been seated 
for 5 min. At least two measures were performed and then a third measure if either the SBP 
or DBP differed by 10%. 
 
A fasting blood sample was taken from the antecubital vein using standard venous puncture 
techniques. All blood samples were processed immediately and aliquots were stored at -80°C 
until assay. Serum low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) 
cholesterol, triglycerides and high sensitivity (hs)-CRP levels were measured at a commercial 














an automated blood analyzer (ADVIA 2400 Chemistry System, Siemens) and hs-CRP by 
chemical analyzer (Cobas Integra 400, Roche). All other biomarkers were measured by 
trained personnel at La Trobe University. Briefly, serum high-sensitivity (hs-)IL-6 levels 
were measured by enzyme‐linked immunosorbent assay (ELISA) (Abcam, #ab46042, 
detection sensitivity <0.81 pg/mL) in duplicate. Serum adiponectin levels were measured by 
ELISA (Invitrogen, Thermofisher Scientific, #KHP0041, detection sensitivity <100 pg/mL) 
in duplicate. Fasting serum glucose levels were measured using enzymatic hexokinase 
method by a chemical analyzer (Indiko, Thermofisher Scientific) in duplicate following blood 
collection in sodium fluoride and oxalate vacutainers. The presence of MetS was calculated 
using the National Cholesterol Education Program ATP III definition[57]. Diagnosis of Type 
2 diabetes mellitus (T2DM) was determined by consulting participant medical history 
records.  
 
2.5. Statistical Analyses  
 
This study was designed to be an exploratory analysis in a pilot cohort of AUSMED 
participants, hence no formal power calculation was performed[58]. Baseline analyses were 
based on the full cohort of participants who started the intervention in order to demonstrate 
the full strength of associations between sociodemographic and clinical characteristics with 
DII scores. The 6-month and change analyses (i.e., baseline to 6-months) were based on 
participants who completed the intervention only. Intention-to-treat analyses was not deemed 
appropriate for the follow-up outcomes assessed, as we aimed to determine whether actual 
change in DII score was related to change in risk markers. An imputation of no change for 
drop-outs would have increased the likelihood of obtaining a significant result and would not 















Data are presented as n (%), means ± SD or medians (interquartile range [IQR]) as 
appropriate. All statistical analyses were conducted using SPSS
®
 statistical package version 
23 (IBM Corp, Released 2015). Normality of continuous variables was assessed by the 
Kolmogorov–Smirnov test. According to this, the Independent Student’s T-test or Mann-
Whitney U test was applied to compare continuous variables. The Chi-square 
 
test was 
performed to compare categorical variables. For all analyses regarding hs-CRP, participants 
with serum levels >10mg/L were excluded as these higher concentrations reflect acute rather 
than chronic inflammation[59]. Pathology marker variables were log transformed (base 10) to 
normalize the distributions and the geometric means were calculated from results. A paired 
Samples T-test was conducted to determine the difference in 6-month change in DII score 
calculated with and without nutrient supplements. McNemar’s test assessed whether the 
proportion of participants with an anti-inflammatory (-) DII score changed.  Logistic 
regression models assessed the odds of elevated hs-CRP levels (>3mg/L)[59] based on DII 
score at baseline and 6-months, presented as odds ratios (OR), 95% confidence intervals (CI); 
this analysis was conducted to allow for comparison of this CHD cohort to results of 
previously reported studies which validated the DII against CRP in other subjects.  
 
Tertiles of change in participant DII scores from baseline to 6-months were created in SPSS 
(participant numbers were deemed insufficient to create quartiles). The tertiles were based on 
having an equal number of participants across three groups rather than pre-defined cut-offs of 
DII change. Least-squared means (95%CI) of cardiometabolic risk markers at 6-months were 
estimated across the tertiles of DII change. Multi-variable general linear models were used to 
estimate the differences (and 95%CI) in the indices of 6-month cardiometabolic risk makers 














assess the linear relationship between these 6-month cardiometabolic risk maker measures 
and change in DII score, while controlling for baseline values. One-way ANOVA (analysis of 
variance), Kruskal-Wallis test or Chi-square 
 
test also assessed change in dietary intake and 
activity levels, and differences in sociodemographic characteristics between these tertiles, 
with post hoc Independent Student’s T-test or Mann-Whitney U test to assess differences 
between specific tertiles. 
 
Covariates included in the logistic regression and general linear models were sex, age, time 
since coronary event, T2DM status and MVPA levels, as well as baseline risk marker values. 
Models were not adjusted for total energy intake because it is one of the DII components. 
Statistical significance was set at p<0.05, except for when multiple post-hoc comparisons 




3.1. Participants  
 
Figure 1 illustrates the pilot study flow of participant appointments. Of the 73 participants 
randomized, 65 started the intervention. There were 9 drop-outs during the intervention 
period due to medical or family related issues or loss to follow up.  Thus, a total of 56 
participants completed the study. There were no significant differences in sociodemographic 
or clinical characteristics between participants who dropped out compared with those who 
completed the 6-month intervention. However, participants who dropped out had a 















Characteristics of the total cohort of participants and according to anti-inflammatory (-) or 
pro-inflammatory (+) DII score at baseline are reported in Table 1. One participant who 
dropped out did not have dietary intake data at baseline and was excluded from all analyses. 
Overall, the cohort were middle to older-aged adults (61.9 ± 9.3 years), mostly male (83%), 
and from multi-ethnic backgrounds. Most participants had experienced an AMI (70%), 28% 
had diagnosed T2DM and the majority were overweight (84%). Few participants were 
current smokers (14%) and the majority had completed a cardiac rehabilitation program 
(80%). All participants were taking medications, of which the most common were anti-
platelets (90%), statins (88%) or a range of anti-hypertensives. Close to half the participants 
were taking supplements (44%). At baseline, mean DII score was almost neutral in terms of 
its inflammatory potential (-0.02 ± 2.72), whereas mean DIIdiet+supplements score was more 
anti-inflammatory (-0.22 ± 2.76).  
 
3.1.1. Pro- versus anti-inflammatory DII 
 
There were a similar number of participants who had anti- (n=31) or pro-inflammatory 
(n=33) DII scores at baseline. The pro-inflammatory DII group had a higher proportion of 
females, a trend toward higher waist circumference and VAT area, and a significantly higher 
total body fat % and SAT area compared to the participants with an anti-inflammatory DII 
score. The pro-inflammatory DII group also tended to have higher prevalence of MetS and 
T2DM and higher plasma glucose levels. There was no significant difference between the 
pro- and anti-inflammatory DII groups for serum lipid levels; in both groups the mean levels 
for LDL, HDL and triglycerides met the reference target for secondary CHD prevention (<1.8 
mmol/L, >1.0 mmol/L and <2.0 mmol/L, respectively)[46]. Mean hs-CRP levels were 1.6 














statistically significant and both groups had a mean hs-CRP level within the normal reference 
range (≤3 mg/L). Serum levels of hs-IL-6 and adiponectin were similar in the pro- compared 
to anti-inflammatory DII groups.  
 
Participants with a pro-inflammatory DII score tended to have a higher proportion of current 
smokers and a lower proportion who had completed cardiac rehabilitation, compared to 
participants with an anti-inflammatory DII score. The anti-inflammatory DII group had 
significantly higher use of omega-3 and multivitamin supplements, and levels of MVPA per 
week.  
 
3.2. Change in DII score 
 
In the participants who completed the diet interventions, there was a significant increase in 
the proportion with an anti-inflammatory (-) DII score, from 28 out of 56 (50%) at baseline to 
37 out of 56 (66%) at 6-months, p=0.049. Mean change in DII score in the pooled study 
cohort following 6-month diet intervention was -0.53 ± 2.65, and this change was not 
significantly different to the mean change in DIIdiet+supplements (-0.60 ± 2.63, p=0.12).  
 
3.3. DII and high sensitivity CRP as dichotomous  
 
Logistic regression analyses for elevated serum hs-CRP levels were performed at baseline 
and 6-months. At both time points, 20% of the assessed participants (13 out of 63 at baseline 
and 11 out of 55 at 6-months) had an elevated hs-CRP i.e., >3 mg/L. Unadjusted analyses 
with DII score as the independent variable demonstrated that higher DII score had a 














95%CI 0.87, 1.38) and at 6-months (OR=1.06, 95%CI 0.81, 1.39). At baseline, the 
association between DII score and increased odds of elevated hs-CRP was greater in the 
model adjusted for sex, age, time since coronary event, T2DM and MVPA levels, although it 
remained nonsignificant (OR=1.16, 95%CI 0.89, 1.51). Conversely, at 6-months, the 
association in the adjusted model was lower (OR=1.04, 95%CI 0.77, 1.39) than the 
unadjusted result. Odds ratios were also calculated for DIIdiet+supplements and the results were 
very similar (see Supplemental Materials, Table S1).  
 
3.4. Tertiles of change in DII 
 
Participants who completed the intervention were categorized into tertiles of change in DII 
score from baseline to 6-months. This resulted in the following tertiles (with range of DII 
change indicated): tertile 1 (T1, n=18) of -7.44 to -1.39, tertile 2 (T2, n=20) of -1.36 to 1.13, 
and tertile 3 (T3, n=18) of  1.18 to 4.00. Table 2 shows the adjusted means for 6-month 
measures of cardiometabolic risk markers, with lower and upper limits of each measure, 
according to tertiles of change in DII score. The corresponding adjusted differences between 
these mean values across the tertiles of change in DII, with T3 as the reference tertile, are 
presented in Table S2 in the Supplemental Materials. Adjusted mean values for weight, waist 
circumference, total body fat %, VAT area, SBP, DBP, LDL, HDL and adiponectin at 6-
months were similar across tertiles. The adjusted mean value for SAT area was higher in T1 
compared to both T2 and T3, however, this did not represent a significant difference across 
tertiles. Adjusted mean values for triglycerides and glucose each decreased linearly across the 
successive tertiles (from reduced to increased DII scores). For triglycerides, this represented a 
significant difference across tertiles (p=0.03), with a significant adjusted difference between 














p=0.01).  For both hs-CRP and hs-IL-6 the adjusted mean values were highest in T2, 
however, for hs-CRP T3 had the lowest value, whereas for hsIL-6 T1 had the lowest value  
This represented a significant difference across tertiles for hs-CRP (p=0.004), with a 
significant adjusted difference between T2 and T3 (0.86, 95%CI 1.66, 6.43 p=0.001) but not 
T1 and T3 (0.30, 95%CI 0.89, 3.63 p=0.10). This also represented a significant difference 
across tertiles for hs-IL-6 (p=0.006), but no significant adjusted differences specifically 
between T1 and T3 (-0.47, 95%CI 0.41, 1.10 p=0.11) or T2 and T3 (0.64, 95%CI 0.90, 2.34, 
p=0.13).  
 
Partial correlation coefficients between these cardiometabolic risk markers at 6-months and 
change in DII score, while controlling for baseline levels of the risk marker, are also 
presented in Table 2. A significant positive correlation was observed between change in DII 
score and 6-month hs-IL-6 levels (r=0.34, 95%CI 0.05, 0.56). A significant negative 
correlation was observed between change in DII score and 6-month triglyceride levels (r=-
0.30, 95%CI -0.51, -0.06). There were no other statistically significant correlations.  
 
The differences between these tertiles for change in DII scores and change in nutrient and 
food group intake and activity levels are presented in Table 3. Participants with greater 
reduction in DII (becoming more anti-inflammatory) across 6-months intervention increased 
their intake of total energy, total fat, MUFA, PUFA, omega-3 and -6, fiber, vitamins C and E, 
folate, potassium, flavones, flavonols, flavonones, isoflavones, vegetables, seafood and olive 
oil, and reduced intake of dairy products. Six-month changes in MVPA levels and sedentary 
time were not significantly different between tertiles. Finally, there were no significant 
differences in measured sociodemographic or clinical characteristics between the tertiles 

















The present study investigated the relationship between DII and cardiometabolic risk 
markers, including the impact of prospective change in DII, in Australian patients with CHD. 
Previous studies have not examined whether dietary-induced improvement in DII improves 
inflammatory markers. Our primary hypothesis that improvement in DII score after 6-months 
intervention with healthy diets (MedDiet or low-fat diet) would lead to reduced levels of 
inflammatory markers was partially supported by this study. A significant positive correlation 
between change in DII and end-intervention values for hs-IL-6, but not hs-CRP or 
adiponectin, was found in linear regression models. Our findings also showed a significant 
difference for change in hs-CRP and hs-IL-6 between tertiles of change in DII; tertile 1 (most 
reduced DII) had the lowest mean value for hs-IL-6 at 6-months; however, tertile 3 (most 
increased DII) had the lowest mean value for hs-CRP at 6-months. There was no significant 
difference between tertiles of DII change for adiponectin at 6-months.  
 
Previous studies investigating DII and inflammation have investigated whether higher DII 
scores were associated with elevated CRP (>3 mg/L). Significant associations have been 
demonstrated in some healthy adult subjects[10, 11, 14] and in those with MetS[60]. In 
contrast, no association has been demonstrated in other studies of healthy subjects, cross-
sectionally[61] or in a prospective cohort with follow-up of 12 years[12]. In the present study 
of CHD patients, a higher DII score was associated with increased odds of mean CRP >3 
mg/L before and after the diet intervention; however, these findings did not reach statistical 














between the tertiles of greatest reduction versus greatest increase in DII score, which was 
unexpected.    
 
Previous research has demonstrated a significant relationship between higher DII score and 
higher levels of IL-6 in large populations of healthy subjects[61, 62] and post-menopausal 
women[14]. In the present cohort of patients with CHD, there was no difference in mean hs-
IL-6 values between participants with a pro- versus anti-inflammatory DII score at baseline. 
However, a reduction in DII score was correlated with a lower hs-IL-6 score at 6-months, 
which has not previously been demonstrated. The significant association we found between 
improvement in DII and hs-IL-6, but not hs-CRP, may be related to the location of 
mechanism of these markers. IL-6 is a pleiotropic cytokine released from activated cells at 
the vascular endothelium, whereas CRP is released from the liver[63]. 
 
Adiponectin is an anti-inflammatory, insulin-sensitizing adipokine[64] and low circulating 
levels are associated with CHD[65]. To our knowledge, only one other study has investigated 
the association between DII and adiponectin, with no difference observed in adiponectin 
levels between quartiles of DII in subjects with MetS[60]. Similarly, in the present study, 
there was no difference in mean adiponectin values between participants with a pro- versus 
anti-inflammatory DII score at baseline. We also demonstrated that a reduction in DII had no 
effect on adiponectin at 6-months. In a previous trial conducted in subjects with MetS, a 
MedDiet with 10% reduction in body weight significantly improved adiponectin, whereas a 
MedDiet in the absence of weight loss had no effect[66]. Our intervention had no energy 
restriction and minimal changes to body weight or composition were observed, which may 















Our ad libitum approach for the diet interventions might also explain the lack of association 
between improvements in DII and changes in anthropometric and body composition 
measurements. We found that participants with a more pro-inflammatory diet had greater 
total body fat %, but no significant differences were seen with BMI or waist circumference at 
baseline. One previous study, which also measured total body fat % by DXA scan, found no 
significant difference in total body fat % between quartiles of participants’ DII scores in a 
cohort of young adults[23]. Two previous studies conducted in Spanish cohorts have shown a 
relationship between DII and anthropometry; after long-term follow-up, incident cases of 
overweight and obesity were related to higher baseline DII scores[17] and DII was associated 
with higher average BMI and waist circumference in the elderly[16]. We also demonstrated a 
stronger association between pro-inflammatory DII score and SAT area compared to VAT 
area at baseline, which was unexpected. Whilst there is a known link between central 
adiposity and increased risk of cardiometabolic diseases[67], there is evidence to support a 
significant overlap between visceral fat distribution and adipose tissue inflammation[68]. No 
previous research has investigated the relationship between DII and compartmental adiposity.  
 
In the present study, participants with an anti- versus pro-inflammatory DII score had 
significantly higher MVPA levels. This would suggest that participants with healthier diets 
also engaged in more physical activity. Other studies have considered whether physical 
activity levels were associated with DII, with one demonstrating that participants with lower 
DII had greater levels[15], whereas others demonstrated no relationship[10, 23]. There is 
evidence to support that exercise intervention significantly reduces levels of CRP and IL-6 in 
patients with CHD[69]. Our trial had no exercise intervention and we found no association 
between change in DII and change in MVPA levels, which demonstrates that changes 















Lipids and/or glucose levels have been related to DII in other studies [10, 15, 60, 70]. We 
showed no association between DII and LDL or HDL cholesterol, but this was not 
unexpected in our subjects who mostly had well-controlled lipid levels at the start of the 
study. There was a trend for higher glucose levels and higher rates of T2DM in participants 
with a pro-inflammatory DII score. There is evidence to support that poor adherence to 
healthy dietary patterns is linked with higher rates of T2DM[71, 72]. We also found that 
participants with greatest increase in DII score had lower 6-month triglyceride levels. This 
unexpected result does not agree with a previous study, which found increased odds of 
elevated triglycerides with higher DII score after 13-years of follow-up[15].  
 
In the present study participants with greatest reduction in DII had increased their intake of 
the nutrients MUFA, omega-3 and -6, fiber, vitamin C and E, folate, potassium and 
flavonoids; and the food groups of vegetables, fruit, nuts, seafood and olive oil, and reduced 
their intake of dairy products. Similarly, a previous intervention trial of a 2-month vegan diet 
significantly reduced DII and led to significantly increased intake of fiber, folate and 
potassium, and decreased intake of calcium (likely reflective of the removal of dairy 
products), and total and saturated fat[25]. In previous cross-sectional analyses, lower DII 
scores were associated with greater consumption of fruits and vegetables[16, 24, 30] and 
cereals, nuts, legumes and fish[16, 24].  
 
This study is strengthened by its prospective nature and detailed assessment of dietary intake. 
We were able to assess how the effect of dietary intervention on DII scores impacts on a 
range of cardiometabolic risk markers, including two of the six inflammatory biomarkers on 














adiposity and the anti-inflammatory biomarker adiponectin. We collected nutrient and food 
intake data via 7-day food diaries that were clarified by the dietitian and calculated the DII 
based on all 45 intake parameters. This method would allow for the anti-inflammatory 
potential of a healthy diet to be more correctly estimated compared to 24-h dietary records or 
food frequency questionnaires, which are the most common methods used to calculate DII in 
other studies[22],  We also assessed whether DII score was impacted by supplement intake.  
 
Our study was limited by being conducted in a small cohort of patients with CHD, of which 
the majority were male. Our results were affected by inadequate statistical power and are not 
necessarily applicable to healthy subjects, other disease populations or women. Only 20% of 
the participants had an elevated CRP value at baseline, which is likely related to the high rate 
of statin and aspirin prescription, as they both have pleiotropic effects on inflammatory 
markers[33, 73]. We were, however, able to demonstrate that participants with the greatest 
reduction in DII had the most improved levels of hs-IL-6 despite adjunct medical therapy. 
The majority of participants were also taking anti-hypertensive medication, which may in 
part explain the lack of association between DII and blood pressure. There were a number of 
participants who dropped out during the intervention and they had significantly more pro-
inflammatory diets at baseline. It is unclear whether they would have achieved dietary 
improvement or changes in risk markers similar to those who completed the intervention. The 
results reported for the effect of change in DII on risk markers included statistical adjustment 
for key potential confounding factors (baseline values, sex, T2DM status, time since coronary 
event and physical activity levels). However, the ancillary results regarding the relationship 
between DII and baseline characteristics and food/nutrient intake changes were not adjusted 
statistically due to their exploratory nature in a small cohort and, therefore, should be 















In conclusion, the present study demonstrated that improvement in DII score towards more 
anti-inflammatory values through healthy diet interventions was linked with reduced levels of 
hs-IL-6 but not hs-CRP, in adult Australian patients with CHD. This study also found that an 
improvement in DII score was associated with higher levels of triglycerides. Changes in DII 
were not associated with changes to other cardiometabolic risk markers, including 
adiponectin, visceral fat, HDL or LDL cholesterol, glucose, blood pressure or measures of 
anthropometry. Significant improvement in DII score was associated with increased intake of 
a variety of healthy foods and nutrients, and total energy. Future research is warranted to 
investigate the impact of change in DII on these risk markers in larger cohorts, other disease 
populations or healthy subjects and with longer-term follow up.   
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Figure captions   
 
Figure 1. Study flow diagram of AUSMED participant appointments and inclusion in 
analyses, 2014-2016. 
a
No comparison of diet study groups, total cohort reported together. 
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Table 1. Characteristics of AUSMED participants between anti(-) or pro(+) 
















































Education level  
Primary School  
















Acute coronary syndrome history  
Acute myocardial infarction  
Coronary artery bypass grafting 
Percutaneous coronary intervention 
Time since cardiac event (months)†   
Type 2 diabetes mellitus  




































Waist circumference (cm) 
Total body fat (%)  
Visceral adipose tissue (cm
2
) 
Subcutaneous adipose tissue (cm
2
) 
Systolic blood pressure (mmHg)  
Diastolic blood pressure (mmHg) 
87.2 ± 18.8 
29.9 ± 5.2 
54 (84.3)  
 
34.0 ± 6.7 
196.0 ± 79.6 
324.5 ± 120.0 
136.5 ± 17.9 
81.9 ± 8.5 
85.6 ± 16.7 
29.1 ± 4.9 
26 (83.9) 
100.7 ± 13.4 
31.4 ± 6.4 
180.1 ± 78.8 
287.8 ± 115.7 
140.0 ± 19.8 
81.8 ± 8.7 
88.7 ± 20.7 
30.7 ± 5.4 
28 (84.8) 
105.8 ± 15.3 
36.5 ± 6.1 
210.4 ± 78.8 
358.0 ± 115.7 
133.1 ± 15.4 











LDL cholesterol (mmol/L) 
HDL cholesterol (mmol/L) 
Triglycerides (mmol/L)  
Glucose (mmol/L) 
High sensitivity CRP (mg/L)
c
 




1.72 ± 1.3 
1.29 ± 1.6 
5.4 ± 1.3 
0.86 ± 3.6 
1.44 ± 3.2 
7.63 ± 1.56 
 
1.76 ± 1.4 
1.19 ± 1.3 
1.19 ± 1.6 
5.06 ± 1.28 
0.68 ± 3.8 
1.39 ± 2.8 
7.31 ± 1.54 
 
1.69 ± 1.6 
1.15 ± 1.3 
1.39 ± 1.7 
5.73 ± 1.29 
1.08 ± 3.2 
1.49 ± 3.6 











Sedentary time (h/wk)  
Current smoker  









187  (201.0) 






















































Angiotensin 2 receptor blocker 
Calcium-channel blocker 
Glucose lowering  
14 (21.9) 
9 (14.1)  
















Vitamin E  
Vitamin C  
Folate  
28 (43.8)  
10 (15.6)  
12 (18.8)  
8 (12.5)  
6 (9.4)  
2 (3.1)  
1 (1.6)  
1 (1.6)  


































-0.02 ± 2.72 
-0.22 ± 2.76 
-2.30 ± 1.58 
-2.46 ± 1.63 
2.12 ± 1.58 
1.89 ± 1.75 
<0.001* 
<0.001* 
Abbreviations: BMI, body mass index; LDL, low density lipoprotein; HDL, high density 
lipoprotein; CRP, C-reactive protein; IL-6, interleukin-6; MVPA, moderate-to-vigorous 
physical activity; wk, week; β, beta; ACE, angiotensin converting enzyme; DII, dietary 
inflammatory index; DIIdiet+supplements, intake of nutrients from supplements included.  
a
Values are n (%), means ± SD or medians (IQR). 
b
Difference between participants with anti- versus pro-inflammatory DII score at baseline, 
Independent Student’s T-test, Mann-Whitney U test or Chi-square test of independence.
 
c
Two participants excluded for value >10mg/L. 
dNegative numbers reflect anti-inflammatory scores, while positive numbers reflect  pro-
inflammatory scores. 
*Significant difference between participants of pro- versus anti-inflammatory DII (without 
supplements) at baseline, p<0.05.  
†Non-parametric variables presented as medians (IQR). 


































Table 2. Adjusted means of cardiometabolic risk markers at 6-months by tertiles of 6-month change in DII score
a




(-7.4 to -1.4) 
n=18 
T2 
(-1.4 to 1.1) 
n=20 
T3 





change DII score 
Anthropometry 
Weight (kg)  

























Body composition  
Total body fat (%) 
Visceral adipose tissue (cm
2
) 




































Systolic blood pressure (mmHg)  



























LDL-cholesterol (mmol/L)  
Triglycerides (mmol/L)  




hs-IL-6 (pg/mL)  

































































Participants were distributed into tertiles of 6-month change in DII score based on having an equal number of participants across three groups 
using SPSS statistical software. Negative numbers reflects anti-inflammatory scores, while positive numbers reflect a pro-inflammatory scores. 
Abbreviations: DII, Dietary inflammatory index;  T, tertile; CI; confidence interval; LDL, low-density lipoprotein; HDL, high-density 
lipoprotein; hs-CRP, High sensitivity C-reactive protein; Hs-IL-6, High sensitivity interleukin-6.  
a 
Adjusted average indices as least-square means with 95%CI from multi-variable linear models adjusted for baseline value, sex, age, type 2 
diabetes mellitus, time since cardiac event and change in moderate-to-vigorous activity levels.  
b
Pearson correlations between risk marker at 6-months and change in DII score, controlling for baseline marker value. Presented as Pearson (r) 
coefficient and 95%CI.   
c
Excluded one participant value for >10 mg/L.  
†All pathology markers were log-transformed and data are presented as difference in adjusted geometric means and confidence intervals have 
been backwards logged.  














Table 3. Baseline to 6-months change in nutrient and food group intake and activity 
levels between tertiles of 6-month change in DII score
a
, AUSMED Study, 2014-2016. 
Intake change variable  
 
T1 
(-7.4 to -1.4) 
T2 
(-1.4 to 1.1) 
T3 








-3.68 ± 1.65 

















Saturated fats (g) 
MUFA (g) 
PUFA (g) 
Omega-3 (g)  
Omega-6 (g)  
Fiber (g)  
Alcohol (g) 
 
176.6 ± 521.9 
-9.5 ± 59.2 
0.8 ± 18.3 
20.5 ± 37.8 
-4.4 ± 9.4 
15.2 (34.6) 
6.51 ± 8.9 
1.07 ± 1.3 
5.45 ± 8.0 
9.7 ± 6.2 
0.0 (8.0) 
 
-61.5 ± 427.9 
-9.9 ± 55.4 
-3.4 ± 26.0 
-1.9 ± 21.9 
-1.3 ± 9.7 
2.4 (11.6)† 
0.25 ± 6.8 
-0.13 ± 0.9†
 
0.55 ± 6.07 
0.2 ± 5.5† 
0.0 (1.9) 
 
-220.4 ± 289.6‡ 
-25.0 ± 46.4 



























Vitamin C (mg)   
Vitamin E (mg)  
Folate (μg) 
Beta-carotene (μg) 










32.6 ± 45.2 
8.7 (12.0) 
68.2 ± 123.8 
4379 (3865) 
-132.8 ± 169.3 
545.0 ± 597.0 
-384.4 (574.8) 
 
17.7 ± 89.3 
-0.6 (5.5)†
 
-13.6 ± 120.6 
2693 (2403) 
-160.8 ±137.6 
164.0 ± 545.6 
-209.9 (898.5) 
 






-232.2 ± 163.7 





















































Wholegrain cereals /d  
Refined cereals /d   
Dairy products /d 
Red meat /wk 
Seafood /wk  
Legumes /wk 
Nuts /wk 
Olive oil /d (g) 
Wine /wk (standard drinks) 
MEDAS score
c 






















































MVPA (min/wk)  









Participants were distributed into tertiles of 6-month change in DII score based on having an 














numbers reflects anti-inflammatory scores, while positive numbers reflect a pro-inflammatory 
scores. 
Abbreviations: DII, Dietary inflammatory index; T, tertile; DIIdiet+supplements, intake of 
nutrients from supplements included; PUFA, polyunsaturated fatty acids; MUFA, 
monounsaturated fatty acids; d, day; wk, week; MEDAS, Mediterranean diet adherence 
screener; MVPA, moderate-to-vigorous physical activity.  
a
Values are means ± SD or medians (IQR). 
b
Difference across tertiles, one-way ANOVA or Kruskal-Wallis test with post-hoc Tukey tests.  
c
Not parameters of the DII.  
d
Food group serve sizes were based on Foodworks8 analyses  
*Significant difference across tertiles, p<0.05.  
†Significant difference between tertile 1 and 2, p<0.025 (Bonferroni correction).  
‡Significant difference between tertile 1 and 3, p<0.025 (Bonferroni correction).  
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